Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : CDC director says boosters needed to protect workers

09/24/2021 | 01:58pm EDT

WASHINGTON, Sept 24 (Reuters) - U.S. Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky on Friday said she recommended booster shots for at-risk adult workers to protect essential workers and minority communities despite the agency's advisory committee voting against the measure.

The U.S. government is rolling out boosters starting with third doses of the Pfizer/BioNTech vaccine for Americans aged 65 and older, adults with underlying medical conditions and those in high-risk working and institutional settings, after health regulators cleared the move this week and Walensky signed off https://www.reuters.com/world/us/us-cdc-advisers-recommend-covid-19-vaccine-boosters-65-older-high-risk-2021-09-23 on it earlier on Friday.

"Many of our frontline workers, essential workers, and those in congregate settings, come from communities that have already been hardest hit," Walensky told reporters. "It was a decision about providing rather than withholding access."

Walensky's decision broke from a recommendation on Thursday by a group of expert outside advisors who felt that a narrower group of people should initially receive the extra shot. She is not obliged to follow the advice of the panel.

"This was a scientific close call. In that situation, it was my call to make," she said at a White House briefing.

Walensky said the CDC would update its guidance on boosters as needed and expects to evaluate in the coming weeks data on boosters for recipients of the Moderna and Johnson & Johnson COVID-19 vaccines.

White House coronavirus response coordinator Jeff Zients, who was also at the briefing said: "We are ready and we are prepared and implementation is happening as we speak. So there are people who will be getting booster shots as early as this afternoon."

(Reporting by Ahmed Aboulenein in Washington and Michael Erman in New Jersey; Additional reporting by Susan Heavey in Washington; Editing by Bill Berkrot)


© Reuters 2021
All news about MODERNA, INC.
04:01pMODERNA : U.S. has administered nearly 414 mln doses of COVID-19 vaccines
RE
03:32pMODERNA : U.S. has administered nearly 414 mln doses of COVID-19 vaccines
RE
03:14pMODERNA : U.S. CDC Says Administered 413,645,478 Doses Of Covid-19 Vaccine As Of Oct 24
RE
12:04aAP NEWS IN BRIEF AT 11 : 04 p.m. EDT
AQ
10/23MODERNA : U.S. CDC Says Delivered 503,521,625 Doses Of Covid-19 Vaccine As Of Oct 23
RE
10/22MODERNA : Canada considers what to do with millions of unused COVID-19 vaccine doses
AQ
10/22MODERNA : U.S. administers nearly 412 mln doses of COVID-19 vaccines - CDC
RE
10/22MODERNA : COVID SCIENCE-COVID-19 vaccines not linked to pregnancy loss; mixing vaccines ma..
RE
10/22CVS HEALTH : Pharmacies Start Offering Moderna COVID-19 Booster Shots
MT
10/22EXPLAINER : Is it time to get a COVID-19 booster? Which one?
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 374 M - -
Net income 2021 12 558 M - -
Net cash 2021 13 559 M - -
P/E ratio 2021 10,9x
Yield 2021 -
Capitalization 132 B 132 B -
EV / Sales 2021 5,80x
EV / Sales 2022 5,10x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Last Close Price 326,54 $
Average target price 295,79 $
Spread / Average Target -9,42%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455
ALNYLAM PHARMACEUTICALS, INC.52.81%23 604